Cryptococcal meningitis

Practical Neurology

Volumn 4, Issue 5, 2004, Pages 274-285

  Day, Jeremy N ^a  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; INDIAN INK; ITRACONAZOLE;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; BRAIN INFARCTION; CEREBROSPINAL FLUID CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENVIRONMENTAL FACTOR; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HUMAN; LIVER DYSFUNCTION; NEPHROTOXICITY; NONHUMAN; PREVALENCE; REVIEW; RIGOR; SEROTYPE; VISUAL IMPAIRMENT; VOMITING;

EID: 7244231119     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1474-7766.2004.00254.x     Document Type: Review

References (32)

1. Aberg JA, Watson J, Segal M & Chang LW (2000) Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clinical Trials 1, 1-6.
2. Bennett JE, Dismukes WE, Duma RJ et al. (1979) A comparison of am hotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. New England Journal of Medicine 301, 126-31.
3. Boekhout T, Theelen B, Diaz M et al. (2001) Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology, 147, 891-907.
4. Boekhout T, van Belkurn A, Leenders; AC et al. (1997) Molecular typing of Cryptococcus neoformans: taxonomic and epidemiological aspects. Int. J. Syst. Bacteriol, 47, 432-42.
5. Casadevall A & Perfect JR (1998) Cryptococcus neoformans American Society for Microbiology Press, Washington.
6. Chen S, Sorrell T, Nimmo G et al. (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clinical Infection and Disease, 31, 499-508.
7. Ellis DH & Pfeiffer TJ (1990) Natural habitat of Cryptococcus neoformans var. gattii. Journal of Clinical Microbiology, 28, 1642-4.
8. Franzot SP, Salkin IF & Casadevall A (1999) Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. Journal of Clinical Microbiology, 37, 838-40.
9. French N, Gray K, Watera C et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 16 1031-8.
10. Friedman GD (1983) The rarity of cryptococcosis in Northern California: the 10-year experience of a large defined population. American Journal of Epidemiology, 117, 230-4.
11. Friedmann PD, Samore MH, Kraemer KL & Calkins DR (1995) Clinical correlates of secondary meningitis in HIV-infected adults. Archives of International Medicine, 155, 2231-7.
12. van der Horst CM, Saag MS, Cloud GA et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine, 337, 15-21.
13. Jenny-Avital ER & Abadi M (2002) Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin. Infect Dis., 35, e128-633.
14. Khoo SH, Bond & Denning DW (1994) Administering amphotericin B - a practical approach. Journal of Antimicrob Chemother, 33 203-13.
15. Lan SH, Chang WN, Lu CH, Lui CC & Chang HW (2001) Cerebral infarction in chronic meningitis: a comparison of tuberculous meningitis and cryptococcal meningitis. Quarterly Journal of Medicine, 94 247-53.
16. Lee SC, Dickson DW & Casadevall A (1996) Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Human Pathology, 27, 839-47.
17. Lewis JL & Rabinovich S (1972) The wide spectrum of cryptococcal infections. American Journal of Medcine, 53, 315-22.
18. Mitchell TG & Perfect JR (1995) Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clinical Microbiological Review, 8, 515-48.
19. Moosa MY & Coovadia YM (1997) Cryptococcal meningitis in burban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clinical Infection andDisease, 24, 131-4.
20. Mwaba P, Mwansa J, Chintu C et al. (2001) Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgraduate Medicine, 77, 769-73.
21. Newton PN, Thai le H, Tip NQ et al. (2002) A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clinical Infection and Disease, 35, 769-72.
22. Ostrosky-Zeichner L, Soto-Hernandez JL, Angeles-Morales V et al. (1996) Effects of pentoxifyHine or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Antimicrob Agents Chemother, 40, 1194-7.
23. Powderley JCMSW (1992) A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. New England Journal of Medicine 326, 793-8.
24. Rex JH, Pappas PG, Karchmer AW et al. (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clinical Infection and Disease, 36, 1221-8.
25. Saag MS, Cloud GA, Graybill JR et al (1999) A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clinical Infection and Disease, 28, 291-6.
26. Saag MS, Graybill RJ, Larsen RA et al. (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clinical Infection and Disease, 30 710-8.
27. Schimpff SC & Bennett JE (1975) Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. Journal of Allergy Clinical Immunology, 55, 430-41.
28. Schwarz P, Dromer F, Lortholary O & Dannaoui E (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother, 47, 3361-4.
29. Seaton RA, Verma N, Naraqi S, Wembri JP & Warrell DA (1997a) The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Transactions of the Royal Society of Tropical Medicine Hygiene, 91, 50-2.
30. Seaton RA, Verma N, Naraqi S, Wembri JP & Warrell DA (1 997b) Visual loss in immmunocompetent patients with Cryptococcus; neoformans; var. gattii meningitis. Transactions of the Royal Society of Tropical Medicine Hygiene, 91, 44-9.
31. UNAIDS/WHO. (2003) AIDS Epidemic Update: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organisation (WHO), 2003:48. AIDS Epidemic Update, 1-37.
32. Vibhagool A, Sungkanuparph S, Mootsikapun P et al. (2003) Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clinical Infection and Disease, 36, 1329-31.